乙型肝炎患者HBsAg血清清除的评估
Evaluation of HBsAg Seroclearance in Patients with Hepatitis B.
作者信息
Taşkın Mehmet Can, Uyanikoglu Ahmet, Cindoglu Cigdem
机构信息
Department of Internal Medicine, Sanliurfa Balikligol State Hospital, Sanliurfa, Turkey.
Department of Gastroenterology, Harran University, Sanliurfa, Turkey.
出版信息
Euroasian J Hepatogastroenterol. 2022 Jul-Dec;12(2):65-68. doi: 10.5005/jp-journals-10018-1352.
OBJECTIVE
Hepatitis B surface antigen (HBsAg) seroclearance/seroconversion is regarded as an indicator of the ultimate immune control of hepatitis B virus (HBV) infections. HBsAg loss is the most important endpoint, as it shows deep suppression of HBV replication and viral protein expression. This study was aimed to retrospectively evaluate the HBsAg seroclearance/seroconversion status in patients with acute or chronic hepatitis B (CHB) diagnosis.
MATERIALS AND METHODS
Patients diagnosed with acute or CHB at the Harran University Faculty of Medicine Department of Gastroenterology between January 2012 and December 2020 were included in this study. This study was designed as a retrospective historical cohort. Experimental analysis of the data was done with the help of the SPSS version 22.0 package program.
RESULTS
Of 1,053 patients with positive HBsAg, 854 patients with sufficient data in their files were included in this study. There were 494 (57.8%) males and 360 (42.2%) females; the mean age was 42.71 ± 14.31 (range 18-88). The mean duration of illness was 86.13 ± 72.92 months. In the 9-year follow-up of 854 patients, 65 (7.9%) of the last HBsAg test were negative and seroclearance had developed. The last anti-HBs test was positive in 49 (75.4%) of 65 patients who developed seroclearance, and it was found that seroconversion had developed. Twenty-seven of 30 (90%) of the patients who developed seroclearance had liver transplantation. Sixteen of 19 (84.2%) of them had acute hepatitis B, 14 of 477 (2.9%) were hepatitis carriers, 5 of 201 (2.5%) had e-negative CHB, 2 of 36 (5.6%) had cirrhosis, and 1 of 43 (2.3%) of them were delta hepatitis who developed seroclearance disease; none of the 38 e-positive CHB patients developed seroclearance.
CONCLUSION
In the 9-year follow-up of patients who were positive for HBsAg at their first admission, approximately one-tenth (7.9%) developed seroclearance, and two-thirds also developed seroconversion. After liver transplantation and acute hepatitis B, almost all patients developed seroclearance, whereas, in approximately 3% of carriers (e-negative CHB and cirrhotic patients) seroclearance developed.
HOW TO CITE THIS ARTICLE
Taşkın MC, Uyanikoglu A, Cindoglu C. Evaluation of HBsAg Seroclearance in Patients with Hepatitis B. Euroasian J Hepato-Gastroenterol 2022;12(2):65-68.
目的
乙肝表面抗原（HBsAg）血清清除/血清学转换被视为乙肝病毒（HBV）感染最终免疫控制的指标。HBsAg消失是最重要的终点，因为它表明HBV复制和病毒蛋白表达受到深度抑制。本研究旨在回顾性评估急性或慢性乙型肝炎（CHB）诊断患者的HBsAg血清清除/血清学转换状态。
材料与方法
纳入2012年1月至2020年12月在哈兰大学医学院胃肠病学系诊断为急性或CHB的患者。本研究设计为回顾性历史队列研究。借助SPSS 22.0版软件包程序对数据进行实验分析。
结果
在1053例HBsAg阳性患者中，854例档案中有足够数据的患者纳入本研究。其中男性494例（57.8%），女性360例（42.2%）；平均年龄为42.71±14.31岁（范围18 - 88岁）。平均病程为86.13±72.92个月。在对854例患者的9年随访中，最后一次HBsAg检测65例（7.9%）为阴性且发生了血清清除。在65例发生血清清除的患者中，49例（75.4%）最后一次抗-HBs检测为阳性，发现发生了血清学转换。发生血清清除的30例患者中有27例（90%）进行了肝移植。其中19例中的16例（84.2%）为急性乙型肝炎，477例中的14例（2.9%）为乙肝携带者，201例中的5例（2.5%）为e抗原阴性CHB，36例中的2例（5.6%）为肝硬化患者，43例中的1例（2.3%）为发生血清清除疾病的丁型肝炎患者；38例e抗原阳性CHB患者均未发生血清清除。
结论
对首次入院时HBsAg阳性患者进行9年随访，约十分之一（7.9%）发生了血清清除，三分之二也发生了血清学转换。肝移植和急性乙型肝炎后，几乎所有患者都发生了血清清除，而在约3%的携带者（e抗原阴性CHB和肝硬化患者）中发生了血清清除。
如何引用本文
Taşkın MC, Uyanikoglu A, Cindoglu C. Evaluation of HBsAg Seroclearance in Patients with Hepatitis B. Euroasian J Hepato-Gastroenterol 2022;12(2):65 - 68.
Zotero 插件